Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Vaccines01:30

Cancer Vaccines

960
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
960
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Journal of medicinal chemistry·2026
Same author

Research Progress and Clinical Translation Challenges of Small-Molecule Inhibitors Targeting PD-L1.

ChemMedChem·2026
Same author

Small-Molecule Inhibitors Targeting PD-1/PD-L1 in Colorectal Cancer: Mechanisms, Challenges, and Clinical Prospects.

ChemMedChem·2025
Same author

PD-L1-targeted novel molecule design: recent advances in immunomodulatory technologies and emerging insights in Cancer therapy.

Bioorganic chemistry·2025
Same author

Innovations in cancer immunotherapy with PD-1 antibody-drug conjugates and their antitumor mechanisms.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

Comparative druggability of PD-1/PD-L1 inhibitors (A56, HD10): Cross-species differences in PD-L1 exposure and efficacy.

Bioorganic & medicinal chemistry·2025

相关实验视频

Updated: Jan 15, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K

新型PD-L1小分子抑制剂推进癌症免疫疗法

Annoor Awadasseid1,2,3, Mengda Wu1,3, Feng Zhang1,3

  • 1Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China.

Anti-cancer agents in medicinal chemistry
|October 6, 2025
PubMed
概括

针对PD-L1/PD-1轴的新型小分子抑制剂提供了新的癌症免疫治疗策略. 我们的研究突出了具有潜力克服耐药性和改善治疗结果的创新化合物.

关键词:
癌症免疫疗法癌症免疫疗法在PD-L1中.检查站封锁检查站封锁药物发展. 药物开发.小分子抑制剂小分子抑制剂

更多相关视频

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.9K

相关实验视频

Last Updated: Jan 15, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.1K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.9K

科学领域:

  • 在瘤学瘤学.
  • 免疫学 免疫学 免疫学
  • 药用化学 医学化学

背景情况:

  • 免疫检查点抑制剂,特别是针对编程细胞死亡蛋白-1 (PD-1) /编程死亡连接体1 (PD-L1) 轴,已经改变了癌症治疗.
  • 对当前生物药物的耐药性需要开发具有改善药理特征和独特作用机制的新型小分子抑制剂 (SMIs).

研究的目的:

  • 审查PD-L1向癌症免疫疗法中SMI的最新进展.
  • 为介绍我们实验室开发的新型小分子PD-L1抑制剂.

主要方法:

  • 2015年至2025年间关于小分子PD-L1抑制剂发表的文章的结构化文献综述.
  • 对于PD-L1/PD-1结合抑制,癌细胞活力和基因表达的新型化合物 (化合物5-10[A56]) 的体外评估.

主要成果:

  • 最近的SMI显示出多种机制,包括直接的PD-1/PD-L1阻断,细胞内PD-L1调节和转录性下调.
  • 化合物7显著抑制了PD-L1mRNA表达;化合物9和10 (A56) 显示了纳米分子结合亲和力.
  • 这些发现表明,有创新的策略可以克服免疫抵抗并增强抗瘤反应.

结论:

  • 显而易见的趋势是多功能PD-L1向的SMI具有细胞外和细胞内机制.
  • 我们实验室的新型化合物显示出进一步优化和临床转换的前景.
  • 口服生物可用性,代谢稳定性和与免疫相关的不良事件的挑战需要进一步调查.